OneSource Specialty Pharma Limited has announced that its partner, Orbicular, has received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This milestone marks the second generic semaglutide approval in Canada, positioning OneSource as a key manufacturing partner for the first generic entrants in this significant market. Commercial supply for the product will be managed through OneSource’s US FDA-approved flagship facility located in Bengaluru.
Strategic Milestone in Global Peptide Markets
OneSource Specialty Pharma Limited has successfully facilitated the second generic semaglutide approval in Canada. This achievement highlights the company’s robust integrated development and manufacturing model. By partnering with Orbicular, which spearheaded the technical and product development program, OneSource provided the end-to-end manufacturing capabilities required for the Canadian regulatory filing.
Leveraging Technical Expertise
According to Mr. Neeraj Sharma, CEO & MD, this achievement underscores the company’s strength in managing complex drug-device-combination programs. The project reinforces OneSource’s growing presence in the competitive landscape of peptide-based injectables. These back-to-back global approvals reflect the company’s ability to maintain high compliance standards while scaling effectively for highly regulated markets.
Future Outlook and Manufacturing Capacity
The company confirmed that the commercial supply for this generic product will be manufactured at its US FDA-approved facility in Bengaluru. This development follows a period of active momentum, including recent product launches in India during the month of March. Looking ahead, OneSource remains committed to expanding its footprint in biologics, sterile injectables, and oral technology to continue providing reliable, high-quality commercialization services to global partners.
Source: BSE
